Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
44 hedge funds and large institutions have $258M invested in Centessa Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 5 closing their positions.
10% more capital invested
Capital invested by funds: $233M → $258M (+$24.4M)
2.86% more ownership
Funds ownership: 67.59% → 70.44% (+2.9%)
0% more funds holding
Funds holding: 44 → 44 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$9.25M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.2M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$1.89M |
| 4 |
Morgan Stanley
New York
|
+$1.57M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
+$1.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$6.58M |
| 2 |
TWM
Tanager Wealth Management
Goring On Thames,
United Kingdom
|
-$4.18M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$450K |
| 4 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$341K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$270K |
CNTA Hedge Fund Activity: Q1 2023 in Review
44 of the 6,285 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q1 2023, worth a combined $258M — up 10% from $233M a quarter earlier.
Fund positioning in CNTA was balanced in Q1 2023: 5 funds opened new positions, 5 closed out, 11 added to existing stakes and 11 trimmed.
The largest buyer was BVF Inc, adding an estimated $9.25M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $6.58M sold.
- 44 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $258M of Centessa Pharmaceuticals stock for Q1 2023, up 10% quarter-over-quarter.
- 5 funds opened new Centessa Pharmaceuticals positions in Q1 2023 and 5 closed out, a net change of 0 holders.
- The largest Centessa Pharmaceuticals buyer in Q1 2023 was BVF Inc, an estimated $9.25M added.
- The largest Centessa Pharmaceuticals seller in Q1 2023 was Janus Henderson Group, an estimated $6.58M sold.
Based on aggregated 13F filings for Q1 2023.